FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1738-1739 October 16, 2008 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: Juweid et al. (September 18 issue)¹ describe the administration of thyrotropin alfa (Thyrogen) to a patient with thyroid cancer who still has a thyroid gland. Genzyme, the manufacturer of Thyrogen, wants to point out that all regulatory bodies, including the Food and Drug Administration, restrict the use of 0.9-mg intramuscular injections of the drug on two consecutive days to patients who have already had a total or near-total thyroidectomy. This is because of substantial transient thyroid swelling and severe hyperthyroidism that could result in some patients with a thyroid gland who receive a large dose of Thyrogen. . . . [Full Text of this Article]

Related Letters:

Diagnosis of Poorly Differentiated Thyroid Cancer with Radioiodine Scanning after Thyrotropin Alfa Stimulation
Juweid M., O'Dorisio T., Milhem M.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:1295-1297, Sep 18, 2008. Correspondence

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.